We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Pfizer has inked a deal to acquire Idun Pharmaceuticals, a San Diego-based biopharmaceutical
firm that owns more than 150 patents covering drug targets, new chemical entities,
drug-screening assays, diagnostics and antibodies.
The healthcare industry, led by biotech and pharmaceutical
companies, garnered a record share of the venture capital (VC) dollars last
year, according to a recent report.
While drug usage is expected to increase after the Medicare prescription drug
benefit starts in 2006, drug spending will continue its slowdown over the next
decade partly because of lower drug prices, according to a new Centers for Medicare
& Medicaid Services (CMS) study.
Alpharma is preparing to take a goodwill impairment charge on its U.S. generics
business -- a decision prompted largely by difficult business conditions in the
generics market, the company said.
Cipher Pharmaceuticals has completed the previously
announced sale of its pharmaceutical research services business, Pharma Medica
Research, to a group led by the current management team of Pharma Medica.
Interpharm Holdings has entered into two separate technology licensing and product
development agreements with Tris Pharma, a specialty drug delivery technology
company.
GPC Biotech, which has its U.S. headquarters in Waltham, said it would buy the
assets of Axxima Pharmaceuticals, a Munich, Germany-based drug discovery firm
for about $18 million in stock.
Alliance Pharmaceutical, through its wholly owned subsidiary PFC Therapeutics,
and LEO Pharma A/S have agreed to amend the previously announced exclusivity
agreement related to the development and marketing of Oxygent in Europe and
Canada.
Geron Corporation and the Biotechnology Research Corporation of Hong Kong announced
the formation of a new company, TA Therapeutics Limited (TAT), in Hong Kong.
Diffusion Pharmaceuticals LLC, a company that discovers and develops novel small-molecule
therapeutics, has reached an agreement with the New Approaches to Brain Tumor
Therapy CNS Consortium (NABTT) for a comprehensive clinical trials program to
test Diffusion's lead drug candidate, trans sodium crocetinate (TSC), as a radiation
sensitizer in the treatment of cancerous tumors.
Aetna Specialty Pharmacy, the joint venture between Aetna and Lake Mary-based
Priority Healthcare Corp., opened for business in its 63,000-square-foot specialty
pharmacy distribution center on March 1.